By Ed Ballard
Royal Philips NV's full-year earnings will take a EUR225 million
($340 million) hit from a delay in the production of CT scanners,
the Dutch company said Tuesday.
The electronics supplier said it has resumed shipping its
Brilliance iCT product from a facility in Cleveland, Ohio,
following external certification of its quality management system,
but the process took longer than expected. Production at the
facility was suspended last March after the U.S. Food and Drug
Administration raised concerns about its manufacturing
controls.
The delay will reduce 2014 earnings before interest, tax and
amortization, or Ebita, by around EUR225 million instead of the
previously-estimated EUR180 million, it said.
"Although these delays have impacted our broader healthcare
performance, we are very pleased to now build further momentum in
delivering strong imaging innovations to our customers," said Chief
Executive Officer Frans van Houten.
Ebita will total EUR255 million in the fourth quarter,
reflecting legal charges, foreign exchange impacts and "softness in
certain markets," as well as the Cleveland production issue,
Philips said.
Write to Ed Ballard at ed.ballard@wsj.com
Access Investor Kit for Royal Philips NV
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=NL0000009538
Access Investor Kit for Royal Philips NV
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US5004723038
Subscribe to WSJ: http://online.wsj.com?mod=djnwires